Clinical trials: Neuron Disease, Motor
Spinal Muscular Atrophy (SMA)
A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular Atrophy
This study is a single-center, open-label, single-arm, non-randomized, single-dose, dose-escalation investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of NKG001 Injection…
- Trial name
- NCT07617779
- Testing
- NKG001
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nikegen Pharmaceutical (Hangzhou) Company Limited
Amyotrophic Lateral Sclerosis (ALS)
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS
Amyotrophic Lateral Sclerosis (ALS) is a severe and incurable neurodegenerative disease of motor neurons with a dramatic socio-economic impact on the national health system.
- Trial name
- PERMEALS (NCT06917924)
- Testing
- lumbar puncture
- Where
- 4 sites in Italy
- Volunteers
- 200 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Amyotrophic Lateral Sclerosis
Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS
ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and…
- Trial name
- NCT01771640
- Testing
- intrathecal injection
- Where
- Iran
- Volunteers
- 8 people
- Sponsor
- Royan Institute
Amyotrophic Lateral Sclerosis
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting…
- Trial name
- NCT03651349
- Testing
- HK-001
- Where
- Taiwan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Everfront Biotech Co., Ltd.
Amyotrophic Lateral Sclerosis
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00230074
- Testing
- TCH346
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Novartis
ALS (Amyotrophic Lateral Sclerosis)
Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)
This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
- Trial name
- ACACIA (NCT07047209)
- Testing
- Digoxin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Dexpramipexole SAD/MAD Study
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
- Trial name
- NCT01449578
- Testing
- Dexpramipexole
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
ALS, ALS (Amyotrophic Lateral Sclerosis)
Healey ALS MyMatch Common Screening Protocol
The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial.
- Conditions
- ALS, ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
- Trial name
- MCSP (NCT07400393)
- Volunteers
- 500 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population.
- Trial name
- NCT02675075
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- VA Office of Research and Development
Spinal Muscular Atrophy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body.
- Trial name
- NCT02633709
- Testing
- Itraconazole, Risdiplam
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
ALS
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic effect after a single dose or at steady state after multiple doses of AMX0035 in adults with sporadic ALS.
- Trial name
- NCT04987671
- Testing
- AMX0035
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Spinal and Bulbar Muscular Atrophy
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
- Trial name
- NCT02024932
- Testing
- BVS857
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Perception of Unpleasant Sensations During Study Procedures in ALS Patients
Diagnosis of Amyotrophic Lateral Sclerosis (ALS) is considered a traumatic life event for both the patient and their next-of-kin/carers, due to the lack of treatment.
- Trial name
- PESALS (NCT06325865)
- Testing
- Interview
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Istituto Auxologico Italiano
LMN Disease
Left Main Intervention in Myocardial Infarction and Acute Coronary Syndromes
Limited data have been published on the management and outcome of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) that involves the left main (LM) coronary artery.
- Trial name
- LIMACS (NCT05701319)
- Testing
- PCI
- Where
- 3 sites in Egypt
- Volunteers
- 500 people
- Sponsor
- Assiut University
Walking Capacity, Amyotrophic Lateral Sclerosis
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
Preclinical and clinical data strongly suggest that administration of salbutamol in ALS patients may improve walking capacity related to motor fatigue by enhancing neuromuscular transmission.
- Trial name
- WALKALS (NCT05860244)
- Testing
- Salbutamol
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Muscle Spasticity
Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function
Background: Primary lateral sclerosis (PLS) is a rare disease. It leads to weakness in the muscle of the arms, legs, and face. People with PLS develop muscle stiffness called spasticity.
- Trial name
- NCT02408900
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor.
- Trial name
- NCT00879593
- Testing
- PtcCO2
- Where
- 2 sites in France
- Volunteers
- 66 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Amyotrophic Lateral Sclerosis
Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS)
A literature review was completed related to the topic of use of the Virtual Seating Coach (VSC) device with clients with Amyotrophic Lateral Sclerosis (ALS) with no results.
- Trial name
- ALS (NCT05742828)
- Testing
- Virtual Seating Coach
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Wake Forest University Health Sciences
Amyotrophic Lateral Sclerosis
Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia
The aim of this study is to obtain an early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia which allows to diagnose the disease in an initial stage and to follow up the patient with optic coherence tomography…
- Trial name
- NCT03285204
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Jose Luis Urcelay Segura
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.